Posted by steve101 on 30th of Jun 2021 at 09:28 am
Atea Pharmaceuticals (
AVIR-5.1%) and Roche's (
OTCQX:RHHBY-0.2%) oral anti-viral drug
for COVID-19, AT-527, reduced viral loads in hospitalized patients,
according to
interim phase 2 data.
Virology analysis showed that at day 2, patients who received
AT-527 experienced a 80% greater mean reduction from
baseline viral load as compared to placebo. This difference in
viral load reduction was continued through day 8.
Strong antiviral activity was also observed in patients with
higher baseline viral loads (above the median of 5.26 log
10).
In this group, 6% of patients on AT-527 achieved SARS-CoV-2
clearance on day 2, 7% on day 8, 33% on day 10, and 31% on day 12
compared to no placebo patients at the same timepoints.
At day 14, 47% of patients in the AT-527 arm and 22% on placebo
had no detectable RNA virus.
AT-527 was safe and well-tolerated in the study.
Newsletter
Subscribe to our email list for regular free market updates
as well as a chance to get coupons!
Atea Pharmaceuticals ( AVIR-5.1%) and Roche's
Posted by steve101 on 30th of Jun 2021 at 09:28 am